Abstract
Purpose Hypertrophic obstructive cardiomyopathy (HOCM) remains a prevalent and clinically significant condition with a global prevalence of 1:200 to 1:500. In Ukraine, the estimated burden is approximately 75,000 patients, although national data remain limited. Since 2016, the Amosov National Institute of Cardiovascular Surgery in Kyiv has been a leading center for HOCM surgery, primarily performing septal myectomy (SM) with concomitant mitral valve (MV) repair. This review summarizes the evolution of the Institute’s surgical program, outcomes, and challenges faced under extraordinary circumstances. Methods Institutional experience with SM and MV repair between 2016 and 2025 was reviewed. Preoperative evaluation included transthoracic echocardiography (TTE), cardiac magnetic resonance (CMR) imaging, and/or computed tomography (CT). A refined transaortic SM technique was applied to optimize septal resection, relieve left ventricular outflow tract (LVOT) obstruction, and address dynamic mitral regurgitation (MR). Results SM consistently reduced LVOT gradients and eliminated MR in the majority of patients. In-hospital mortality remained below 1%, with a low incidence of major complications directly attributable to myectomy. Despite significant external pressures, including the coronavirus disease 2019 (COVID-19) pandemic and the ongoing full-scale war in Ukraine, surgical activity continued without interruption. Innovations in operative techniques and perioperative management further enhanced safety and outcomes. Conclusion The Amosov Institute has established a high-performing national program for HOCM surgery, demonstrating durable results despite unprecedented challenges. Ongoing refinement of minimally invasive strategies and strengthened international collaboration remain essential to address the global shortage of experienced myectomy surgeons and ensure wider access to advanced surgical care.

This publication has 17 references indexed in Scilit: